List of Excipients in Branded Drug FENTANYL TRANSDERMAL SYSTEM

« Back to Dashboard

Generic Drugs Containing FENTANYL TRANSDERMAL SYSTEM

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	fentanyl transdermal system	21695-975	DIMETHICONE
Rebel Distributors Corp	fentanyl transdermal system	21695-975	DIMETHICONE 350
Rebel Distributors Corp	fentanyl transdermal system	21695-975	DIPROPYLENE GLYCOL
Rebel Distributors Corp	fentanyl transdermal system	21695-975	ETHYLENE-VINYL ACETATE COPOLYMER
Rebel Distributors Corp	fentanyl transdermal system	21695-975	HEPTANE

What are the Most Frequently-Used Excipients in FENTANYL TRANSDERMAL SYSTEM?

# Of NDCs	Excipient
4	DIMETHICONE
4	DIMETHICONE 350
4	DIPROPYLENE GLYCOL
4	ETHYLENE-VINYL ACETATE COPOLYMER
4	HEPTANE

Fentanyl Transdermal System Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 21, 2026

Fentanyl transdermal systems are mature, regulated products with limited opportunity for basic molecule differentiation. The commercial value is concentrated in adhesive performance, controlled drug release, residual-drug management, manufacturing reliability, abuse-risk mitigation, and market access. Original Duragesic patent protection has expired, and U.S. competition is primarily governed by FDA approval, controlled-substance compliance, supply reliability, product quality, and device or formulation improvements rather than blocking composition-of-matter patents.

What is the commercial status of fentanyl transdermal systems?

Fentanyl transdermal systems deliver fentanyl continuously through the skin, generally over 72 hours in labeled adult use. The products are approved for management of persistent, moderate-to-severe chronic pain in opioid-tolerant patients. They are not indicated for acute pain, postoperative pain, intermittent pain, or opioid-naive patients because of respiratory-depression risk.[1]

Commercial attribute	Market implication
Active ingredient	Fentanyl, a highly potent synthetic opioid
Dosage form	Transdermal patch
Typical labeled delivery strengths	12, 25, 37.5, 50, 62.5, 75, and 100 mcg/hour, depending on product
Reference product	Duragesic, originally associated with Janssen
FDA pathway for competitors	Abbreviated New Drug Application, with product-specific requirements
Controlled-substance category	Schedule II in the United States
Principal barriers	Abuse risk, dose uniformity, adhesion, residual drug, manufacturing controls, and supply-chain security
Main commercial competition	Generic fentanyl patches and differentiated transdermal delivery systems

The product class is mature but technically demanding. A patch must deliver a narrow dose range through variable skin conditions while remaining attached during bathing, sweating, movement, and temperature changes. A small change in adhesive, solvent, polymer, or drug-loading profile can affect systemic exposure.

What excipients are used in fentanyl transdermal systems?

The excipient system depends on the delivery architecture. Fentanyl patches generally use one of two designs: a reservoir system or a drug-in-adhesive matrix system.

Reservoir-system excipients

A reservoir patch stores fentanyl in a liquid or gel formulation behind a rate-controlling membrane. The membrane controls drug flux, while the adhesive holds the system on the skin.

Typical functional materials include:

Excipient or material class	Function
Alcohol or other volatile solvent	Solubilizes fentanyl and supports partitioning into the skin
Water	Supports gel structure and drug mobility
Cellulose derivative	Thickens or stabilizes the reservoir
Rate-controlling polymer membrane	Regulates fentanyl release
Polyisobutylene or related adhesive	Provides skin adhesion
Polyester or polyethylene backing	Protects the reservoir and controls handling
Release liner	Protects the adhesive before application

The reference Duragesic design used a drug reservoir with a rate-controlling membrane. Product labeling identifies fentanyl, alcohol, water, and hydroxyethyl cellulose among the formulation components, with additional patch-layer materials described in the product design.[1]

Reservoir systems can provide predictable release but have a higher failure-consequence profile. If the pouch, membrane, or seal is damaged, drug release may change materially. The remaining drug in a used reservoir patch also creates a significant diversion and accidental-exposure concern.

Drug-in-adhesive matrix systems

Matrix patches disperse fentanyl directly in an adhesive layer. The drug-containing adhesive is laminated between a backing layer and a release liner.

Typical excipient functions include:

• Acrylic or silicone pressure-sensitive adhesive
• Polymeric tackifiers or cohesion modifiers
• Solubilizers or plasticizers
• Penetration-modifying agents
• Polyester, polyethylene, or similar backing films
• Release liners with controlled peel characteristics

Matrix systems generally have a thinner construction and can reduce the number of discrete layers. They may improve manufacturing efficiency and reduce reservoir-related failure modes. Their principal technical challenge is maintaining dose uniformity and consistent fentanyl diffusion throughout the adhesive during shelf life.

A matrix product is not automatically lower risk. The patch can still retain clinically meaningful fentanyl after use, and adhesive transfer or partial detachment can affect exposure.

How should manufacturers design an excipient strategy for fentanyl patches?

The strongest excipient strategy prioritizes consistent skin flux and safe handling over maximum drug loading.

Skin permeation and dose control

Fentanyl is potent and sufficiently lipophilic for transdermal delivery, but skin permeability varies by age, hydration, disease state, body site, and temperature. Excipients should be selected to produce a controlled flux profile without causing excessive initial release.

Key development targets include:

1. Consistent delivery across relevant skin donors.
2. Low initial burst after application.
3. Limited sensitivity to ambient and body temperature.
4. Adequate drug solubility over the shelf life.
5. No meaningful crystallization or phase separation.
6. Stable delivery after repeated flexing and movement.

Solvent selection is commercially important. A solvent that increases fentanyl mobility may improve delivery but can also increase burst release, adhesive migration, skin irritation, or residual-drug content.

Adhesion and wear performance

Adhesion is one of the most valuable differentiation areas. A patch that lifts early can reduce exposure; a patch that bonds too aggressively can damage skin or leave adhesive residue.

An effective adhesive system should demonstrate:

• Initial tack after application
• Continuous adhesion for the labeled wear period
• Resistance to sweat and bathing
• Low cold flow
• Low residue after removal
• Controlled peel force
• Compatibility with fentanyl and the backing film
• Limited skin irritation and sensitization

The FDA has treated adhesion as a clinically relevant performance attribute for transdermal and topical delivery systems. Product developers should evaluate adhesion under wet, warm, flexed, and repeated-contact conditions rather than relying only on laboratory peel testing.[2]

Temperature resistance

Heat can accelerate fentanyl release and increase systemic exposure. The labeling for fentanyl transdermal systems warns against external heat sources, fever, hot tubs, saunas, and other conditions that raise skin temperature.[1]

Excipients and laminate design should therefore minimize temperature-driven release changes. A commercially valuable patch can differentiate through improved resistance to moderate environmental variation, but it cannot eliminate the fundamental pharmacokinetic risk created by excessive heat.

Skin tolerability

Fentanyl patches remain in contact with skin for an extended period. Irritation, erythema, allergic contact dermatitis, and adhesive residue can reduce adherence and lead to treatment discontinuation.

Excipient screening should address:

• Irritation after single and repeated application
• Sensitization potential
• Residual monomers and impurities
• Solvent evaporation
• Adhesive residue
• Interaction with lotions, creams, and skin cleansers

The commercial objective is not simply a stronger adhesive. It is a reliable adhesive with acceptable tolerability over repeated dosing.

What formulations are protected by fentanyl patch patents?

Most original U.S. patent protection for fentanyl transdermal delivery related to reservoir architecture, rate-controlling membranes, drug-containing gels, patch construction, and manufacturing methods. The foundational Duragesic-era patents are expired or no longer expected to block ordinary generic fentanyl patch development.

Patent category	Historical relevance	Current commercial significance
Transdermal fentanyl composition	Established delivery of fentanyl through skin	Foundational protection is expired
Reservoir and membrane design	Controlled drug release	Relevant as prior art; new improvements may be patentable
Matrix adhesive formulation	Reduced-layer patch architecture	Potential area for improvement patents
Adhesion and wear systems	Improved attachment and tolerability	Stronger opportunity for later-filed patents
Manufacturing and lamination	Improved content uniformity and yield	Can create process or trade-secret barriers
Abuse-risk reduction	Reduced residual drug or tamper resistance	Potential future patent area
Pediatric or low-dose delivery	Dose flexibility and safer handling	Potentially valuable if clinically and regulatorily supported

Patentability now depends on a specific technical improvement, not the general concept of delivering fentanyl through a patch. Claims directed only to fentanyl, a transdermal patch, or routine excipient substitution face substantial prior-art risk.

When did fentanyl transdermal exclusivity expire?

The original market exclusivity for fentanyl transdermal systems has ended. Duragesic launched in the United States in the 1990s, and generic fentanyl patches subsequently entered through ANDA approvals. The core commercial issue is no longer whether generic entry is legally possible. It is whether a proposed product can satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, adhesion, labeling, and controlled-substance security.

The Orange Book remains the relevant source for current reference-product listings, patents, and exclusivity information. Because Orange Book entries can change by supplement and product presentation, commercial diligence should be conducted at the specific NDA and strength level rather than by relying on the Duragesic brand name alone.[3]

What is the Orange Book status of fentanyl transdermal systems?

The Orange Book identifies FDA-approved reference products and approved generic products. For fentanyl patches, the key diligence points are:

• Whether the proposed generic references the same listed drug.
• Whether the strength and dosage form match the reference product.
• Whether any listed patent remains relevant to the targeted presentation.
• Whether an ANDA applicant must submit a Paragraph IV certification.
• Whether a first-filer or 180-day exclusivity issue applies.
• Whether the product has an active, approved labeling difference.
• Whether the target product remains commercially available.

Because foundational fentanyl patch patents are old, a new ANDA is more likely to face product-specific regulatory and technical hurdles than a significant patent blockade. A Paragraph IV certification could still arise if a later-listed patent covers a specific formulation, process, delivery profile, or device feature.

Which companies are challenging or competing with fentanyl transdermal products?

Competition comes from generic manufacturers, specialty pharmaceutical companies, and alternative opioid-delivery products. Generic patch suppliers have included major ANDA manufacturers and contract manufacturers, although company participation varies by strength, manufacturing site, and time.

The competitive landscape is divided into four groups:

1. Conventional generic fentanyl patches.
2. Alternative matrix or adhesive designs.
3. Other opioid formulations, including oral extended-release products.
4. Nonopioid and interventional pain therapies.

Generic competition is constrained by controlled-substance quotas, pharmacovigilance requirements, diversion controls, and the reputational and regulatory risk associated with opioid products. A technically equivalent patch does not guarantee stable supply or attractive margins.

What generic entry risks exist for fentanyl transdermal systems?

The principal generic-entry risks are operational and regulatory.

Bioequivalence and pharmacokinetics

FDA may evaluate fentanyl exposure through pharmacokinetic parameters such as area under the curve and maximum concentration. Transdermal products can also require attention to adhesion, adhesion-related exposure changes, and residual drug. A formulation that appears equivalent in vitro may produce different in vivo performance because of skin and adhesive interactions.

Content uniformity

Fentanyl is used at a low concentration relative to the total patch mass. Manufacturing must control drug distribution across the entire adhesive or reservoir. Small mixing, coating, or lamination errors can create clinically important variability.

Residual drug

Used fentanyl patches may retain substantial drug. Packaging, labeling, disposal instructions, and manufacturing controls must address accidental exposure, diversion, and worker safety. Residual-drug performance can become a regulatory differentiator and a litigation risk.

Adhesion failures

Premature lifting can lead to treatment failure and patient complaints. Excessive adhesion can cause skin injury. Recalls involving adhesion, content uniformity, or packaging defects can damage a supplier’s position quickly because substitution options may be limited.

What commercial opportunities exist for fentanyl transdermal excipients?

The largest opportunity is not a new generic excipient combination. It is a defensible performance improvement with measurable clinical or manufacturing value.

High-value opportunity areas

Opportunity	Commercial value	Patent potential
Longer and more reliable wear	Reduces replacement failures	Moderate
Lower skin irritation	Supports persistence and adherence	Moderate
Improved temperature robustness	May reduce exposure variability	High if technically demonstrated
Lower residual fentanyl	Improves safety and disposal profile	Moderate to high
Better low-dose strengths	Expands titration options	Moderate
Reduced adhesive residue	Improves patient acceptability	Moderate
Solvent-free manufacturing	May reduce emissions and process risk	Moderate
Improved coating yield	Reduces cost of goods	Often better protected as know-how
Tamper-resistant construction	Supports controlled-substance risk management	Moderate to high
More stable supply of critical polymers	Reduces manufacturing interruption risk	Usually contractual or trade-secret protection

Excipient suppliers can create value through qualified adhesive platforms, controlled-release membranes, high-purity cellulose derivatives, and specialized backing or liner systems. The strongest supplier position usually combines regulatory history, validated quality, technical support, and dual-source manufacturing.

How does fentanyl transdermal protection compare with other transdermal drugs?

Fentanyl has a stronger safety and control burden than many nonopioid transdermal products. That burden changes the commercial value of excipient innovation.

Attribute	Fentanyl patch	Noncontrolled transdermal drug
Dose potency	Extremely high	Usually lower
Residual drug concern	Severe	Generally lower
Diversion risk	High	Usually limited
Temperature sensitivity	Clinically significant	Variable
Adhesion importance	High	High
Regulatory scrutiny	High because of opioid risk	Product-dependent
Manufacturing controls	Extensive	Standard pharmaceutical controls
Market differentiation	Safety, reliability, supply	Convenience, duration, comfort

A fentanyl patch improvement must pass both ordinary transdermal product requirements and controlled-substance risk scrutiny.

What licensing deals and partnership models are available?

Licensing opportunities are most credible in five areas:

• Adhesive platforms already used in approved transdermal products.
• Manufacturing processes that improve coating uniformity or yield.
• Low-residual-drug or tamper-resistant patch constructions.
• Specialized backing, membrane, and liner technologies.
• Regional commercialization rights for approved generic products.

Licensing a broad fentanyl patch concept has limited value because the foundational technology is mature. A stronger transaction would identify a specific product advantage, define ownership of formulation and process patents, allocate controlled-substance compliance obligations, and include supply continuity commitments.

Contract manufacturing is also strategically relevant. A reliable CMO with validated fentanyl handling, coating, pouching, serialization, and DEA-compliant controls can be more valuable than a nominally broad patent estate.

What patent litigation affects fentanyl transdermal systems?

The major patent disputes historically focused on branded transdermal delivery technology and generic entry. Current litigation risk is more likely to involve:

• Later-developed matrix formulations.
• Adhesive compositions.
• Device or packaging claims.
• Manufacturing-process patents.
• Labeling and method-of-use claims.
• Product liability and recall disputes.
• Trade-secret claims involving coating or lamination processes.

A company assessing entry should separate three risks: Orange Book patent risk, non-Orange Book patent risk, and regulatory or product-liability risk. For an ordinary generic fentanyl patch, the second and third categories may be more commercially important than the expired foundational patents.

What is the FDA regulatory status of fentanyl transdermal systems?

FDA-approved fentanyl transdermal systems remain prescription, Schedule II products. The FDA labeling restricts use to opioid-tolerant patients and contains prominent warnings for respiratory depression, accidental exposure, heat-related overdose, medication errors, and improper disposal.[1]

A new product may require:

• ANDA approval if it qualifies as a generic equivalent.
• NDA approval if it introduces a clinically meaningful difference.
• Human factors work for any new delivery or packaging system.
• Product-specific adhesion and performance studies.
• Controlled-substance manufacturing and distribution controls.
• Postmarketing surveillance and risk-management compliance.

FDA’s approval framework does not treat an excipient change as commercially trivial. A new adhesive or solvent can affect bioequivalence, skin tolerability, release kinetics, stability, and labeling.

How strong is the patent estate for fentanyl transdermal systems?

The foundational estate is weak as a barrier to conventional U.S. generic entry because the principal early patents have expired. The improvement estate can still be meaningful where claims cover a narrow and technically distinctive combination of:

• Fentanyl concentration and distribution.
• Adhesive chemistry.
• Membrane permeability.
• Patch-layer geometry.
• Temperature response.
• Residual-drug reduction.
• Manufacturing parameters.
• Packaging and tamper resistance.

Trade secrets may provide greater practical protection than patents for coating speed, drying conditions, mixing order, solvent removal, lamination pressure, and in-process testing. Those parameters can determine yield and quality without being fully disclosed in a patent.

What revenue exposure exists in the fentanyl patch market?

Revenue exposure is concentrated in established generic suppliers, hospitals, pain-treatment channels, and specialty distributors. The market is smaller than the market for oral analgesics but can have attractive characteristics for a reliable supplier:

• Repeat prescription demand.
• Limited number of qualified manufacturers.
• High technical switching costs.
• Controlled-substance compliance barriers.
• Potential supply shortages when a site fails inspection or exits the market.

Revenue is vulnerable to opioid-prescribing restrictions, payer substitution, safety concerns, manufacturing interruptions, recalls, and regulatory action. A company should value the product based on net price, quota availability, production yield, and supply continuity rather than unit demand alone.

Key Takeaways

• Fentanyl transdermal systems are mature products with expired foundational U.S. patent protection.
• Commercial differentiation is concentrated in adhesion, release control, temperature robustness, residual-drug reduction, and manufacturing reliability.
• Excipients include solvents, cellulose derivatives, pressure-sensitive adhesives, backing films, release liners, and rate-controlling membranes.
• Matrix and reservoir designs have different failure modes and intellectual-property profiles.
• Ordinary generic entry is more likely to face FDA, quality, controlled-substance, and supply-chain barriers than a foundational patent blockade.
• Later-filed patents can protect specific adhesive, membrane, packaging, abuse-risk, and manufacturing improvements.
• Excipient suppliers with qualified materials, regulatory history, and supply redundancy have a stronger commercial position than suppliers offering undifferentiated polymers.
• Licensing value depends on a measurable product advantage and enforceable control of formulation, process, or delivery technology.

FAQs

Are fentanyl patch excipients listed in FDA labeling?

Yes. The reference-product labeling identifies key formulation and patch components, but the exact excipient profile varies by manufacturer and product architecture. DailyMed and approved product labels are the primary sources for product-specific composition.[1]

Can a company patent a new fentanyl patch adhesive?

Yes, if the adhesive provides a novel and non-obvious composition or measurable technical result. Broad claims covering the use of an adhesive patch to deliver fentanyl are unlikely to provide strong protection because of extensive prior art.

Does a generic fentanyl patch need to use the same excipients as Duragesic?

No. A generic generally must demonstrate pharmaceutical equivalence and bioequivalence, but it may use different inactive ingredients subject to FDA requirements. The alternative excipients must not compromise safety, performance, stability, or labeling.

Is a fentanyl matrix patch safer than a reservoir patch?

Not inherently. Matrix designs may reduce certain reservoir-failure modes, but both designs can retain clinically significant fentanyl and can cause overdose after heat exposure, misuse, or accidental transfer.

What is the most attractive commercial improvement for a fentanyl patch?

Reliable adhesion with lower skin irritation and controlled temperature response is among the strongest opportunities. The improvement must be demonstrated through product-performance, stability, adhesion, pharmacokinetic, and regulatory data.

References

1. U.S. Food and Drug Administration. (2023). Duragesic (fentanyl transdermal system) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2019). Transdermal and topical delivery systems: Product development and quality considerations. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2020). Abbreviated new drug application submissions: Suitability of dosage form guidance for industry. FDA.

5. U.S. Food and Drug Administration. (2022). Fentanyl transdermal system labeling and safety communications. FDA.